-
Daniel Kirschner, PhD
… from 1971-1974 as a postdoctoral fellow of the National Multiple Sclerosis Society. Following Research Associate …
-
R. Lee Mosley, MS, PhD
… glatiramer acetate (GA), a peptide polymer used to treat multiple sclerosis (MS) patients, significantly protect …
-
Measurement of 1-deoxysphingolipids in Parkinson’s Disease Plasma
… Rationale: The sphingolipid metabolic pathway is large and complex, comprising hundreds of lipids critical to … both normal and abnormal ceramide synthesis pathways in 300 blood samples, including both Parkinson’s patients and …
-
Potent Inhibitors of Deubiquitinating Enzyme USP14 as Inducers of Parkin-independent Mitophagy
… Study Rationale: We are working on a small, drug-like compound that has potential therapeutic application in Parkinson's disease. This … deubiquitinases … Research Grant … Daniel J. Finley, PhD …
-
CDC Selects Parkinson's as One of the First Diseases Included in New Database
November 19, 2018
… , called the National Neurological Conditions Surveillance System (NNCSS). Parkinson's is one of two diseases that … of the CDC's working group to build and implement this new system. At a meeting earlier this year at the CDC’s …
-
Estrogenic Neuroprotection and the Parkinson's Disease Phenotype
… slowing the degeneration of the nigrostriatal dopaminergic system in PD. This proposal will study several novel … estrogen analogs in a rat primary mesencephalic culture system and the most potent and efficacious compounds will be …